Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human TIGIT Protein, MYC/DDK-tagged

Cat.No. : TIGIT-1037H
Product Overview : Recombinant human TIGIT protein, fused to MYC/DDK tag at C-terminus, was expressed in HEK293.
  • Specification
  • Gene Information
  • Related Products
Description : This gene encodes a member of the PVR (poliovirus receptor) family of immunoglobin proteins. The product of this gene is expressed on several classes of T cells including follicular B helper T cells (TFH). The protein has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses.[provided by RefSeq, Sep 2009].
Source : HEK293
Species : Human
Tag : MYC/DDK
Form : 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
Molecular Mass : 26.1 kDa
Purity : >50 ug/mL as determined by microplate BCA method
Concentration : >50 ug/mL as determined by microplate BCA method
Gene Name : TIGIT T cell immunoreceptor with Ig and ITIM domains [ Homo sapiens ]
Official Symbol : TIGIT
Synonyms : VSIG9; VSTM3; WUCAM
Gene ID : 201633
mRNA Refseq : NM_173799
Protein Refseq : NP_776160
MIM : 612859
UniProt ID : Q495A1

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
In which types of cancers is TIGIT inhibition being investigated? 12/02/2022

TIGIT inhibitors are being studied in a range of cancers, including lung cancer, breast cancer, and melanoma, among others.

How is TIGIT relevant in autoimmune diseases? 05/14/2022

TIGIT is being explored as a potential target for treating autoimmune diseases by modulating immune responses to prevent excessive inflammation.

What clinical applications does TIGIT have in cancer therapy? 06/11/2020

TIGIT is being explored as a potential target for cancer immunotherapy, with drugs designed to block TIGIT and enhance the immune system's ability to attack cancer cells.

How does TIGIT differ from other immune checkpoint proteins like PD-1 and CTLA-4? 04/22/2020

TIGIT operates as an immune checkpoint, similar to PD-1 and CTLA-4, but it has distinct mechanisms of action and may regulate different aspects of the immune response.

Are there any potential side effects associated with TIGIT-targeted therapies? 01/12/2016

As with any immunotherapy, potential side effects may include immune-related adverse events such as inflammation in various organs, but the specific profile is still under investigation.

Customer Reviews (3)

Write a review
Reviews
11/25/2022

    With its well-characterized nature and availability in various formats, the TIGIT protein is an advantageous tool that aids researchers in achieving their scientific goals.

    08/05/2017

      Whether it's troubleshooting issues, optimizing experimental protocols, or providing detailed information about the protein, the manufacturer's support team is dedicated to helping researchers overcome any challenges they may encounter.

      05/21/2017

        The manufacturer also ensures that the TIGIT protein is well-characterized, with extensive documentation on its functional properties.

        Ask a Question for All TIGIT Products

        Required fields are marked with *

        My Review for All TIGIT Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends